Description
Teoxane Teosyal® PureSense Redensity 1 (1×3 mL)
Teosyal® PureSense Redensity 1 is a non-cross-linked hyaluronic acid (HA) skin booster medical device developed by Teoxane Laboratories to improve skin hydration, redensification, and early signs of aging across the face, neck, and décolletage. Its formula combines 15 mg/mL of free high-molecular-weight hyaluronic acid with a patented dermo-restructuring complex of amino acids, antioxidants, minerals, and vitamin B6 — plus 0.3 % lidocaine to enhance patient comfort during injection. The nutrient-enriched gel is injected into the superficial to mid dermis to support tissue hydration, firmness, and prevention of fine lines and wrinkles. Teosyal Redensity 1 is intended for use by trained healthcare professionals experienced in aesthetic injectable treatments.
Teosyal Redensity 1 is distinct from traditional volumising dermal fillers; rather than restoring volume, it focuses on skin texture improvement, enhanced hydration and redensification of aged or dehydrated skin, helping to support a fresher and more resilient appearance.
What Teosyal Redensity 1 Is Similar To
Teosyal Redensity 1 belongs to the Teosyal® PureSense line of skin boosters and can be regarded alongside other nutrient-enriched HA treatments that target skin quality rather than volumetric augmentation. Like Profhilo® or other HA-based hydration boosters, Redensity 1 uses unmodified free HA to attract and retain water in tissues, thereby enhancing hydration and general skin health. However, in addition to HA, Redensity 1 incorporates a dermo-restructuring complex of amino acids, antioxidants, minerals, and vitamin B6 designed to support cellular activity and dermal integrity.
In contrast to thicker cross-linked HA fillers (e.g., Juvederm® or Restylane® volumisers), which are designed for deep wrinkle correction and volume restoration, Teosyal Redensity 1 emphasises subtle improvement in skin texture, tonicity, and hydration. This comparison is provided for clinical orientation only and does not imply interchangeability.
Treatment Areas / Indications
According to manufacturer and distributor documentation, Teosyal PureSense Redensity 1 is indicated for:
-
Skin redensification and hydration of the face, neck, and décolletage.
-
Prevention and reduction of fine lines and early signs of aging.
-
Improvement of skin texture, firmness, and overall luminosity.
Treatment areas and injection depth should be determined by a qualified medical professional based on individual assessment and aesthetic goals.
Usage / Administration (IFU-Only)
-
Injection depth: Superficial to mid dermis, depending on treatment area.
-
Volume per injection site: Not provided by manufacturer.
-
Needle gauge: Typically supplied with 30 G × ½″ needles.
-
Frequency / number of sessions: Treatment protocols often involve multiple sessions spaced approximately 3 weeks apart, with maintenance sessions recommended periodically; official guidance may vary.
-
Professional-use disclaimer: Administered only by qualified healthcare professionals experienced in dermal injections under aseptic conditions.
If any parameter is omitted from official IFU or product documentation, it is recorded as “not provided by manufacturer.”
Ingredient List
-
Hyaluronic acid (HA): 15 mg/mL of non-cross-linked HA.
-
Lidocaine hydrochloride: 0.3 % (w/w) to enhance injection comfort.
-
Dermo-restructuring complex:
-
8 amino acids (e.g., glycine, lysine, threonine, proline, isoleucine, leucine, valine, arginine)
-
3 antioxidants (e.g., glutathione, N-acetyl-L-cysteine, alpha-lipoic acid)
-
2 minerals (zinc, copper)
-
Vitamin B6
All excipients and supplemental buffering agents are included per IFU and ensure compatibility with HA.
-
Presentation & Longevity
-
Presentation: 1 × 3 mL pre-filled sterile syringe (traceability labelling included).
-
Shelf life: Not specified in public documentation; refer to product packaging for expiry date.
-
Longevity (treatment duration): According to manufacturer guidance for PureSense products, Teosyal Redensity 1 has an estimated in-vivo lifetime of at least 3 months following treatment. Individual duration may vary with skin condition, injection technique, and lifestyle factors.
Safety Notes / Contraindications
-
Contraindicated in patients with known hypersensitivity to hyaluronic acid, lidocaine, or any component of the formulation.
-
Avoid injection into areas with active infection, inflammation, or compromised skin integrity.
-
Strict aseptic technique and detailed anatomical knowledge are essential to minimise risks.
-
Refer to the official Instructions for Use for complete warnings, precautions, and post-treatment care.
Regulatory Status
Teosyal PureSense Redensity 1 is a CE-marked medical device authorised for aesthetic use in Europe. Users should verify region-specific regulatory details (e.g., UKCA) via product packaging or formal IFU documentation.
FAQ
1. What is Teosyal Redensity 1?
Teosyal Redensity 1 is a nutrient-enriched skin booster based on non-cross-linked hyaluronic acid combined with antioxidants, amino acids, minerals, and vitamin B6 to hydrate, redensify and improve skin quality. It includes 0.3 % lidocaine to enhance injection comfort and is used in superficial dermal layers.
2. How long does Teosyal Redensity 1 last?
According to manufacturer guidance for Teosyal PureSense products, the estimated in-vivo lifetime of Redensity 1 is at least 3 months after treatment. Effects can vary based on skin characteristics, treatment protocol, and injection technique.
3. What areas can Teosyal Redensity 1 be used on?
Teosyal Redensity 1 is typically injected into the face, neck, and décolletage to improve hydration, skin texture, and reduce early signs of aging.
4. Is Teosyal Redensity 1 a traditional volumising filler?
No — Redensity 1 is a skin booster, not a structural volume filler. Its primary purpose is skin redensification and hydration, rather than restoring deep volume like thicker cross-linked HA fillers.
5. Can Teosyal Redensity 1 be combined with other aesthetic treatments?
Treatment protocols may include combining Redensity 1 with other aesthetic procedures, but this should be determined by a qualified clinician. Official IFU instructions do not prescribe combination therapies and such decisions remain at the practitioner’s discretion.
